Our transactions

Our Track Record

Over the last couple of years, Agile has successfully advised on over €1.1 billion worth of transactions and has closed 18 transactions in the last 18–24 months with global investors or strategic players across Europe, North America, Asia, and beyond.

2024 €40M

Cilcare

Cilcare completes a €40 million Series A to accelerate the development of innovative treatments for early hearing loss.

Biotech - Series A
2024 €7M

RIBOPRO

RIBOPRO Secures Series A funding to accelerate mRNA-Based technologies.

CDMO - Series A
2024 $16M

Discure Technologies

Discure Technologies developer of the Discure System, a bioelectronic implantable device for the treatment of degenerative disc disease (DDD), announces a $16 million series A.

Medtech - Series A
2024 €400M

Cilcare

Cilcare, a leading biotech company specializing in auditory sciences, announces a €400 million agreement with Shionogi.

Biotech - Licensing
2024 €6.5M

BIOPHTA

BIOPHTA raises €6.5 million seed funding to transition its new standard of care for eye diseases to the clinical stage.

Biotech - Series A
2024 €8M

Acticor Biotech

Acticor Biotech completes a capital increase for a total gross amount of €8 million.

Biotech - PIPE
2024 $110M

Undisclosed

New York based biotech company raises $110M series C to develop innovative treatments for schizophrenia.

Biotech - Series C
2023 €2.6M

Acticor Biotech

Acticor Biotech completes a capital increase for a total gross amount of approximately €2.6 million.

Biotech - PIPE
2023 Undisclosed

APICES

Spanish CRO APICES boosts its expansion and growth plans with the integration of the French CRO Kappa Santé.

CRO - M&A Buy-side
2023 Undisclosed

Pherecydes

Merger of Erytech and Pherecydes and renamed Phaxiam Therapeutics.

Biotech - Reverse Merger
2023 €16.5M

Undisclosed

A company developing a microfluidic Cell and Gene Therapy manufacturing platform raises €16.5 million in seed funding.

Cell Therapy CDMO - Seed
2023 €12.2M

Acticor Biotech

Acticor Biotech successfully completes a capital increase for a total gross amount of €12.2 million.

Biotech - PIPE
2023 Undisclosed

Backbone

Companion Spine acquires Backbone SAS, expanding its portfolio of medical implants dedicated to treating spine and back pain.

Medtech - M&A Sell-side
2022 €8M

Lattice Medical

LATTICE MEDICAL, a French Medtech company providing patients and healthcare professionals with personalized tissue reconstruction solutions, closed a second round of financing of €8 million.

Medtech - Series A
2022 €27M

Incepto

Incepto, the AI platform for medical imaging, raised €27 million to support its European development.

Digital Health - Series B
2022 $7M

Neurofenix

Neurofenix closes a $7 million Series A financing round led with AlbionVC as lead investor, with the participation of HTH, InHealth Ventures, and of existing investors.

Digital Health - Series A
2022 €4.2M

Ludocare

Ludocare, specialist in digital therapies dedicated to pediatrics, announces a €4.2 million fund-raising round.

Digital Health - Seed
2022 Undisclosed

Spine Innovations

Spineway, a specialist in innovative implants for severe spinal pathologies, acquires 100% of the capital of Spine Innovations, a French company specializing in cervical and lumbar disc prostheses.

Medtech - M&A Sell-side
2022 $42M

Domain Therapeutics

Domain Therapeutics raises $42 million Series A financing to accelerate clinical development of its best-in-class and first-in-class immuno-oncology programs.

Biotech - Series A
2021 €15M

FineHeart

FineHeart S.A, a preclinical medical device designed to address the unmet need of patients suffering from severe heart failure, raised a €15 million series B funding round.

Medtech - Series B
2021 €15.5M

Acticor Biotech

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market, with €15.5 million raised.

Biotech - IPO
2020 €2.25M

PKvitality

PKvitality, a French company specialized in bio wearables, has signed an agreement with Beurer GmBH, providing PKvitality with €2.25 million funding to further develop the K’Watch and reach FIH.

Medtech - Series A
2019 €22.3M

Acticor Biotech

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, has raised €7 million in addition to its Series B, now completed at €22.3 million.

Biotech - Series B
2019 €2.5M

TransCure bioServices

TransCure bioServices, a French one-stop-shop preclinical services company dedicated to in-vivo full human immune system mouse models, completed a €2.5 million funding with Financière Arbevel.

CRO - Growth funding
2018 $26M

Valcare Medical

Valcare Medical, a medtech company developing innovative minimally-invasive technologies for the treatment of mitral regurgitation, raises $26 millions series B led by a Chinese Medical Device company.

Medtech - Series B
2018 €60M

Acticor Biotech

Acticor biotech signed a €60 million regional development and commercialization agreement with China Medical System Holding Limited®.

Biotech - Licensing
2018 €15.1M

EOS Imaging

EOS imaging has entered into a binding agreement with Fosun Pharmaceutical AG, an indirect subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., for c. €15.1 million.

Medtech - PIPE
2018 €29.5M

EOS Imaging

EOS IMAGING, the pioneer of 2D/3D imaging and data solutions for orthopedics, completed an offering of bonds convertible for a nominal amount of c. €29.5 million.

Medtech - Convertible Bonds
2018 €11.8M

STENTYS

STENTYS, a medtech company commercializing the Xposition S self-apposing coronary stent, acquired MINVASYS, independent specialist in innovative coronary devices marketed worldwide, for €11.8 million.

Medtech - M&A Sell-side
2017 €20M

Cellnovo

Cellnovo concludes a loan agreement for up to €20 million from the European Investment Bank.

Medtech - Loan Agreement
2017 €17.5M

Cellnovo

Cellnovo Group, a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announced a capital raise of €17.5 million.

Medtech - PIPE
2016 €5.4M

Cellnovo

Cellnovo raises circa €5.4 million in capital increase without preferential subscription rights.

Medtech - PIPE